Technical Analysis for TGTX - TG Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 5.0 -1.96% -0.10
TGTX closed down 1.96 percent on Thursday, December 13, 2018, on 1.21 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical TGTX trend table...

Date Alert Name Type % Chg
Dec 13 Fell Below 20 DMA Bearish 0.00%
Dec 13 Bollinger Band Squeeze Range Contraction 0.00%
Dec 12 50 DMA Resistance Bearish -1.96%
Dec 12 Shooting Star Candlestick Bearish -1.96%
Dec 12 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.96%
Dec 12 Crossed Above 20 DMA Bullish -1.96%
Dec 12 Bollinger Band Squeeze Range Contraction -1.96%
Dec 12 Doji - Bearish? Reversal -1.96%
Dec 11 20 DMA Resistance Bearish -0.79%
Dec 11 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.79%

Older signals for TGTX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

TG Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company is developing two advanced therapies targeting hematological malignancies. The TGTX-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes, which is in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. The TGR-1202 is an orally available PI3K delta inhibitor believed to be important in the proliferation and survival of B-lymphocytes. TG Therapeutics, Inc. is headquartered in New York, New York.
Is TGTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Dec 12 3 Beaten-Down Biotech Stocks That Could Bounce Back in 2019
Dec 12 Recent Analysis Shows Verizon Communications, MGM Resorts International, Exelon, Axon Enterprise, M.D.C., and TG Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth
Dec 5 Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Trevena, Inc.
Dec 4 Is TG Therapeutics Inc’s (NASDAQ:TGTX) CEO Overpaid Relative To Its Peers?
Dec 4 TG Therapeutics' U2 combo + chemo shows positive action in early-stage lymphoma study; shares up 2%
Dec 4 TG Therapeutics, Inc. Announces Follow-Up Data from the Triple Combination of Ublituximab, Umbralisib, and Bendamustine in Patients with DLBCL and FL at 60th American Society of Hematology Annual Meeting and Exposition
Dec 3 CLASS ACTION DEADLINE for TGTX, ACHC and ADNT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Dec 3 DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against TG Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Dec 3 FINAL DEADLINE ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against TG Therapeutics, Inc. (TGTX) & Lead Plaintiff Deadline - December 3, 2018
Dec 3 TG Therapeutics, Inc. Announces Oral Presentation of Follow-Up Data from the Triple Combination of Ublituximab, Umbralisib, and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter’s Transformation at 60th American Society of Hematology A...
See more TGTX news...
Indicator Value
52 Week High 17.35
52 Week Low 4.2
Average Volume 1,219,003
200-Day Moving Average 10.983
50-Day Moving Average 5.1714
20-Day Moving Average 5.0795
10-Day Moving Average 5.057
Average True Range 0.293
ADX 11.38
+DI 18.0444
-DI 18.5857
Chandelier Exit (Long, 3 ATRs ) 4.731
Chandelier Exit (Short, 3 ATRs ) 5.649
Upper Bollinger Band 5.3248
Lower Bollinger Band 4.8342
Percent B (%b) 0.34
BandWidth 9.658431
MACD Line -0.1059
MACD Signal Line -0.1423
MACD Histogram 0.0364
Fundamentals Value
Market Cap 311.55 Million
Num Shares 62.3 Million
EPS -1.95
Price-to-Earnings (P/E) Ratio -2.56
Price-to-Sales 3189.49
Price-to-Book 6.24
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.32
Resistance 3 (R3) 5.32 5.22 5.26
Resistance 2 (R2) 5.22 5.14 5.22 5.24
Resistance 1 (R1) 5.11 5.09 5.06 5.11 5.23
Pivot Point 5.01 5.01 4.99 5.01 5.01
Support 1 (S1) 4.90 4.93 4.85 4.90 4.77
Support 2 (S2) 4.80 4.88 4.80 4.76
Support 3 (S3) 4.69 4.80 4.74
Support 4 (S4) 4.69